Abstract
This study aimed to evaluate the efficacy of cinobufotalin combined with gefitinib in the treatment of lung cancer. A549 cells were treated with gefitinib, cinobufotalin, or cinobufotalin plus gefitinib. MTT assay, annexin-V/PI staining and flow cytometry, TUNEL staining, DCFH-DA staining, Western blot, and real-time RT-PCR were performed to investigate the synergistic inhibitory effect of cinobufotalin combined with gefitinib on the growth of A549 cells. Results showed that cinobufotalin synergized with gefitinib displayed inhibited cell viability and enhanced apoptosis in the combination group. Cinobufotalin combined with gefitinib induced a significant enhancement in reactive oxygen species (ROS) production accompanied by cell cycle arrest in the S phase arrest, characterized by upregulation of p21 and downregulation of cyclin A, cyclin E, and CDK2. Besides, cinobufotalin plus gefitinib downregulated the levels of HGF and c-Met. In summary, cinobufotalin combined with gefitinib impedes viability and facilitates apoptosis of A549 cells, indicating that the combined therapy might be a new promising treatment for lung cancer patients who are resistant to gefitinib.
References
Apr 28, 2007·Science·Jeffrey A EngelmanPasi A Jänne
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David JackmanVincent A Miller
Feb 12, 2010·Future Oncology·Luca Toschi, Federico Cappuzzo
Aug 18, 2012·Chemico-biological Interactions·Heba EmamTakashi Kondo
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangLecia V Sequist
Sep 10, 2014·Biochemical and Biophysical Research Communications·Sheng KaiHui Zhao
Jun 10, 2015·The Oncologist·Yen-Han TsengYuh-Min Chen
Jun 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tina CasconeJohn V Heymach
Sep 30, 2017·The Lancet Oncology·Yi-Long WuTony S Mok
Jun 2, 2018·Journal of Hematology & Oncology·Nithila A JosephKuan-Chih Chow
Aug 24, 2018·Cancers·Oshin MirandaJill M Siegfried
Oct 24, 2018·International Journal of Cancer. Journal International Du Cancer·J FerlayF Bray
Jan 6, 2019·International Journal of Molecular Sciences·Masayuki Takeda, Kazuhiko Nakagawa
Feb 1, 2019·Journal of Cellular and Molecular Medicine·Min LuPing Liu
Feb 6, 2019·Cancer Management and Research·Tao LuQun Wang
Mar 3, 2019·Cancer Communications·Fang WangHai-Yun Wang
Jul 2, 2019·Life Sciences·Guojun WangXiefu Zhang
Aug 30, 2019·Medicine·Fan ZhangTiantian Xu
Dec 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nele Van Der SteenPatrick Pauwels
Jan 1, 2020·Cancer Medicine·Jun LiHong Chen
Feb 20, 2020·Biomolecules·Ha-Na OhJung-Hyun Shim
Mar 3, 2020·Journal of Drug Targeting·Rui LiLiang Li
Apr 2, 2020·Journal of Cancer·Liqiang QianQuangen Gao
Apr 18, 2020·Expert Review of Anticancer Therapy·Pauline HuloJaafar Bennouna